Quantitative analysis of spermatogenesis in rats made azoospermic with compound CDRI 84/35

Abstract

Compound CDRI 84/35 (1-formyl-4-dichloroacetamidopiperazine) was reported to exert its effect on seminiferous epithelium without affecting Leydig cells and accessory sex organs. Adult rats administered CDRI 84/35 (100 mg/kg body weight for 15 days followed by 25 mg/kg) showed a significant atrophy of testis indicating 21.8 ± 4.4, 79.6 ± 5.3, 94.8 ± 2.1 and 79.5 ± 2.1% abnormal tubules at 22, 41, 54, and 64 days following treatment at the time of autopsy). The Sertoli cell-germ cell ratio showed a significant reduction in number of primary spermatocytes and spermatids during the treatment. Marked decrease in pachytene spermatocytes and in stages of spermatogenesis was observed on day 54. In contrast, the testes in estradiol benzoate (EB; 5 g/rat/day) treated rats showed 64.6% ± 21.85% abnormal tubules at day 22 and almost all affected tubules on from day 41 onwards, exhibiting a significant decline in number of spermatocytes and spermatids, while spermatogonia were affected only at 64 days of treatment. Reversibility studies showed 76.5% ± 2.1% normal tubules with significant inhibition in spermatogenesis following 60 days cessation of CDRI 84/35. At 120 days recovery, 74.7% ± 18.8% testicular tubules revealed quantitatively normal spermatogenesis, whereas 25.3% ± 18.8% tubules showed incomplete recovery of spermatogenesis until 120 days. The present study revealed a marked inhibition of spermatogenesis at the pachytene spermatocyte stage by CDRI 84/35 compared to EB in the seminiferous epithelium of rat. Its antispermatogenic effect was found to be irreversible up to 120 days.